Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Rises By 103.0%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 121,000 shares, a growth of 103.0% from the December 15th total of 59,600 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average daily volume of 153,600 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Trading Up 1.0 %

Shares of Bolt Biotherapeutics stock traded up $0.01 during trading hours on Wednesday, hitting $0.52. The company’s stock had a trading volume of 333,812 shares, compared to its average volume of 182,246. The stock has a market cap of $19.90 million, a price-to-earnings ratio of -0.30 and a beta of 0.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. Bolt Biotherapeutics has a twelve month low of $0.48 and a twelve month high of $1.56. The firm has a fifty day moving average of $0.57 and a 200-day moving average of $0.64.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.02 million. Research analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. FMR LLC grew its position in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,386 shares of the company’s stock after purchasing an additional 28,773 shares during the period. FMR LLC owned approximately 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.